CoChat

Glucocorticoid Resistance: Is It a Requisite for Increased Cytokine Production in Depression? A Systematic Review and Meta-Analysis

Open access
Perrin, Andrew J., Horowitz, Mark A., Roelofs, Jacob, Zunszain, Patricia A., Pariante, Carmine M. · 2019 · Frontiers in Psychiatry

The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; none of the 62 sources its claims cite is checked for support yet.

Abstract

Glucocorticoid resistance – reduced function of the glucocorticoid receptor (GR) – is seen in many depressed patients. It is argued that this resistance to glucocorticoids leads to failure of normal feedback regulation on the immune system. High levels of pro-inflammatory cytokines result. We sought to identify evidence supporting or refuting a link between glucocorticoid resistance and immune dysregulation in depression, and to summarize retrieved evidence in aggregate form. Methods: We systematically reviewed and meta-analysed studies that examined cytokine levels in depressed patients compared with controls and that also reported a measure of glucocorticoid resistance. These measures included plasma cortisol, the dexamethasone suppression test (DST), GR expression levels and the results of in vitro assays of GR function. We conducted four separate meta-analyses to test for moderating effects of glucocorticoid resistance on cytokine production in depression. After sub-grouping 32 studies by the ratio of cortisol levels in patients compared with controls, we observed a trend for increasing glucocorticoid resistance (i.e., the most hypercortisolemic patients) to be associated with increased production of IL-6 [d = 0.94; 95% CI (0.29, 1.59)] and TNF-α [d = 0.46; 95% CI (0.12, 0.79)]. We stratified 9 studies that reported DST results by relative glucocorticoid resistance between patients and controls, identifying a trend for higher glucocorticoid resistance in patients, compared with controls, to be associated with higher cytokine production in patients (170 patients and 187 controls). This was particularly evident when studies were sub-grouped by source of cytokine – plasma [d = 1.04; 95% CI (0.57, 1.50)] versus in vitro [d = 0.24; 95% CI (-0.20, 0.67)]. Stratifying the 4 studies (147 patients and 118 controls) that used in vitro assays of GR function or GR expression to quantify glucocorticoid resistance revealed variable contributions to cytokine production in patients compared with controls [overall effect size d = 1.35; 95% CI (0.53, 2.18)]. Our work provides some support for a model conceptualizing glucocorticoid resistance as a requisite for increased inflammation in depression. The limited number of studies identified highlights the need for purpose-designed investigations that directly examine the relationship between glucocorticoid resistance and cytokine production in depression.

Overview

CoChat Summary

TL;DR

This systematic review and meta-analysis found only modest support for glucocorticoid resistance as a requisite for increased cytokine production in depression, with the largest effects when resistance was indexed by plasma/salivary cortisol. Across 32 cortisol studies, IL-6 and TNF-α were higher in depressed patients, but combined DST/in vitro/GR-expression analyses showed no evident positive correlation between glucocorticoid resistance and inflammation.

Key findings

  • In 32 studies grouped by patient:control plasma cortisol ratio, hypercortisolemic patients showed a larger IL-6 effect size (d = 0.94; 95% CI 0.29–1.59) than eucortisolemic patients (d = 0.52; 95% CI 0.26–0.77), though the difference was not statistically significant; overall IL-6 effect was d = 0.61 (95% CI 0.36–0.85) based on 1,850 patients and 1,232 controls.
  • TNF-α overall effect was d = 0.40 (95% CI 0.12–0.68); hypercortisolemic patients showed d = 0.46 (95% CI 0.12–0.79) versus eucortisolemic d = 0.39 (95% CI −0.19 to 0.98), a non-significant trend, with insufficient hypocortisolemic studies for comparison.
  • Nine DST/endocrine suppression studies (170 patients, 187 controls) showed overall higher cytokine levels in patients (d = 0.81; 95% CI 0.39–1.23); plasma cytokine studies showed d = 1.04 (95% CI 0.57–1.50) versus in vitro stimulated studies d = 0.24 (95% CI −0.20 to 0.67), a significant subgroup difference (p = 0.01).
  • Four in vitro GR function/GR expression studies (147 patients, 118 controls) had an overall effect d = 1.35 (95% CI 0.53–2.18) but no obvious positive association between glucocorticoid resistance and cytokine production; combining these with DST studies (302 patients, 277 controls) gave d = 1.02 (95% CI 0.55–1.49) with no evident positive correlation between glucocorticoid resistance and inflammation.

Methods

  • PRISMA systematic review and meta-analysis using three complementary searches of MEDLINE, EMBASE, PsycInfo, and the Cochrane Database from origin to October 31, 2018, for adult (>17 years) depressed patients and controls diagnosed by standardized clinical/diagnostic interview, with both a glucocorticoid-resistance measure and cytokine levels; exclusions included bipolar/psychotic/substance use disorders, acute infection within 2 weeks, and BMI >30, with allowances for chronic conditions or immune-modulating therapies if <10% or matched.
  • Glucocorticoid resistance was assessed by relative plasma/salivary cortisol ratio (patient:control), DST or other endocrine suppression test, in vitro GR function, and GR expression; data were extracted as means/SDs or estimated from medians/ranges using the Wan method, and a “glucocorticoid resistance index” was calculated for DST/endocrine and in vitro/GR-expression studies.
  • Random-effects meta-analyses in RevMan5 used Cohen’s d; cytokines were meta-analyzed only if reported by five or more studies; subgroup/moderator analyses examined cortisol ratio, DST/endocrine suppression, in vitro/GR expression, and combined data, with heterogeneity assessed by τ² and I², sensitivity analyses, and funnel plots.

Limitations

  • Stated: the small number of study subjects and studies limited precision of effect-size estimates; included studies were cross-sectional and not purpose-designed to test the relationship; heterogeneity was high; the authors call for large studies with multiple objective measures of glucocorticoid resistance and medication-free patients.
  • Stated measurement limitations: serum cortisol is not always elevated in depression and diurnal timing varied (94% of studies measured morning cortisol, generally 0700–1100, not all in the post-awakening hour); the DST measures peripheral resistance only and cut-offs varied; in vitro/GR-expression findings may not translate to the CNS; the glucocorticoid resistance index uses relative differences, so small absolute differences can appear large.
  • Evident from the text: many patients were taking antidepressants (69% of cortisol studies, 7/9 DST studies, and 40–100% of in vitro/GR-expression studies), some studies had data gaps, and heterogeneity remained high in several pooled analyses (e.g., I² = 84% for IL-6 and 87% for the in vitro/GR-expression analysis), which may limit certainty.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fpsyt.2019.00423

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Search strategy and article review process. Details of this are found in text. Abbreviations are as follows: DST, dexamethasone suppression test; GR, glucocorticoid receptor.
Figure 1 Search strategy and article review process. Details of this are found in text. Abbreviations are as follows: DST, dexamethasone suppression test; GR, glucocorticoid receptor.CC BY · PubMed Central
Figure 2 Forest plot analysing effect size for IL-6, sub-grouping studies by relative plasma cortisol levels. Hypercortisolemic corresponds to patient:control plasma cortisol ratio > 1.2; eucortisolemic corresponds to patient:control plasma cortisol ratio > 0.8 or < 1.2; hypocortisolemic corresponds to patient:control plasma cortisol ratio < 0.8.
Figure 2 Forest plot analysing effect size for IL-6, sub-grouping studies by relative plasma cortisol levels. Hypercortisolemic corresponds to patient:control plasma cortisol ratio > 1.2; eucortisolemic corresponds to patient:control plasma cortisol ratio > 0.8 or < 1.2; hypocortisolemic corresponds to patient:control plasma cortisol ratio < 0.8.CC BY · PubMed Central
Figure 3 Forest plot analysing effect size for TNF-α, sub-grouping studies by relative plasma cortisol levels. Hypercortisolemic corresponds to patient:control plasma cortisol ratio > 1.2; eucortisolemic corresponds to patient:control plasma cortisol ratio > 0.8 or < 1,2; hypocortisolemic corresponds to patient:control plasma cortisol ratio < 0.8.
Figure 3 Forest plot analysing effect size for TNF-α, sub-grouping studies by relative plasma cortisol levels. Hypercortisolemic corresponds to patient:control plasma cortisol ratio > 1.2; eucortisolemic corresponds to patient:control plasma cortisol ratio > 0.8 or < 1,2; hypocortisolemic corresponds to patient:control plasma cortisol ratio < 0.8.CC BY · PubMed Central
Figure 4 (A) Forest plot reporting effect size for cytokine stratified by “glucocorticoid resistance index” (GRI) calculated from DST or other endocrine suppression test. The specific cytokine selected for inclusion (based on criteria enumerated in Methods) is listed after the study name. Studies are ranked by GRI from high to low. (B) Forest plot of studies in (A) sub-grouped by source of cytokine. Stimulated levels were obtained from in vitro cultured cells using the stimulant specified in Table 2 . Rank based on GRI (listed) as in (A).
Figure 4 (A) Forest plot reporting effect size for cytokine stratified by “glucocorticoid resistance index” (GRI) calculated from DST or other endocrine suppression test. The specific cytokine selected for inclusion (based on criteria enumerated in Methods) is listed after the study name. Studies are ranked by GRI from high to low. (B) Forest plot of studies in (A) sub-grouped by source of cytokine. Stimulated levels were obtained from in vitro cultured cells using the stimulant specified in Table 2 . Rank based on GRI (listed) as in (A).CC BY · PubMed Central
Figure 5 Forest plot reporting effect size for cytokine stratified by “glucocorticoid resistance index” (GRI) calculated from in vitro GR functional assay or GR expression. The specific cytokine selected for inclusion (based on criteria enumerated in Methods) is listed after the study name. Studies are ranked by GRI from high to low.
Figure 5 Forest plot reporting effect size for cytokine stratified by “glucocorticoid resistance index” (GRI) calculated from in vitro GR functional assay or GR expression. The specific cytokine selected for inclusion (based on criteria enumerated in Methods) is listed after the study name. Studies are ranked by GRI from high to low.CC BY · PubMed Central
Figure 6 Forest plot reporting effect size for cytokine stratified by “glucocorticoid resistance index” (GRI) calculated from DST or other endocrine suppression test results, in vitro GR functional assay or GR expression. Studies are ranked by GRI from high to low. All study data included in this figure were previously shown in Figures 4 or 5 . Only the data for Carvalho et al. (13) from Figure 4A was used in this analysis as inclusion of data from this study from both Figure 4A and Figure 5 would have introduced duplication bias. Listed beside each study is the glucocorticoid resistance outcome measure that was used to calculate the GRI.
Figure 6 Forest plot reporting effect size for cytokine stratified by “glucocorticoid resistance index” (GRI) calculated from DST or other endocrine suppression test results, in vitro GR functional assay or GR expression. Studies are ranked by GRI from high to low. All study data included in this figure were previously shown in Figures 4 or 5 . Only the data for Carvalho et al. (13) from Figure 4A was used in this analysis as inclusion of data from this study from both Figure 4A and Figure 5 would have introduced duplication bias. Listed beside each study is the glucocorticoid resistance outcome measure that was used to calculate the GRI.CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 2 Not valid · 56 Not checked · 141 Own results and interpretations

78 more claims

Create a free account to see all 199 claims and to verify the 62 references still open.

See all claims — free account
  • Probably not a substantial claim. 89
  • It may state two separate claims as one. 45
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Show all 82 references

Research works printed but not linked: 1

  1. 2014, Review Manager (RevMan) [Computer program]

Cited by

See all 112

Metadata

Authors
Perrin, A. J., Horowitz, M. A., Roelofs, J., Zunszain, P. A., & Pariante, C. M.
Affiliations
  • University of British Columbia (CA)
  • King's College London (GB)
Corresponding author
Perrin, Andrew J.
Venue
Frontiers in Psychiatry
Published
2019-06-28
Volume
10
Pages
423-423
ISSN
1664-0640 (ISSN-L)
OpenAlex
W2955135686
Cited by
112
References
82
Citations by year
2026: 15 · 2025: 16 · 2024: 18 · 2023: 14 · 2022: 13 · 2021: 12 · 2020: 23 · 2019: 1
FWCI
1.17
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (publishedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • South London and Maudsley NHS Foundation Trust (MR/L014815/1)
  • NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
  • Royal College of Physicians and Surgeons of Canada
  • National Institute for Health and Care Research (NF-SI-0616-10074)
  • King's College London
  • Medical Research Council (MR/N029488/1, MR/L014815/1, MR/J002739/1)
Topics
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
depression, cytokine production, glucocorticoid receptor, hypercortisolism, dexamethasone suppression test, interleukin-6, TNF-α, immune dysregulation, hypothalamic-pituitary-adrenal axis, inflammatory cytokines, glucocorticoid receptor expression, plasma cortisol, moderating effect

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.